UPDATE : Friday, August 7, 2020
HOME Pharma
Jeil’s oral cancer treatment wins extended indication for NSCLC
  • By Shim Hyun-tai
  • Published 2020.04.06 15:33
  • Updated 2020.04.06 15:33
  • comments 0

Jeil Pharmaceutical said Monday that its oral anticancer drug, Ts-1, has obtained additional indication for treating metastatic non-small cell lung cancer (NSCLC) patients or locally advanced patients who have received platinum-based chemotherapy.

Ts-1 is an oral chemotherapy combination of tegafur, gimeracil, and oteracil potassium that has been used to treat advanced gastric cancer.

Now, Ts-1 can be prescribed for locally advanced or metastatic NSCLC with the existing permit to treat postoperative chemotherapy of gastric cancer, advanced and metastatic or recurrent gastric cancer, head and neck cancer, and locally advanced or metastatic pancreatic cancer.

Ts-1 showed non-inferiority by recording a median of 12.75 months of overall survival with a hazard ratio of 0.945 and a 95-percent confidence interval of 0.833 to 1.073 compared to 12.52 of Docetaxel monotherapy, in the East Asia S-1 Trial in Lung Cancer.

Ts-1 monotherapy can provide a new treatment option for NSCLC patients, as it won recognition for significantly improved effects with a p-value of 0.0065 in some of the items measured in comparison to Docetaxel monotherapy, the company said.

The European Organization evaluated the quality of life for the Research and Treatment of Cancer Quality of Life Questionnaire QLQ-C30.

There are various NSCLC treatments, but most of them are injections. Ts-1 is the only oral Fluorouracil (5-FU) anti-cancer medication.


<© Korea Biomedical Review, All rights reserved.>

Other articles by Shim Hyun-tai
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top